Anavex Life Sciences Corp.
(NASDAQ : AVXL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading AVXL News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.18%165.741.2%$778.89m
INCYIncyte Corporation
0.48%139.641.7%$592.23m
GILDGilead Sciences, Inc.
0.03%67.511.0%$577.68m
CELGCelgene Corporation
0.13%123.381.0%$494.27m
BIIBBiogen Inc.
-0.21%274.821.3%$452.48m
REGNRegeneron Pharmaceuticals, Inc.
2.19%373.002.1%$320.06m
KITEKite Pharma, Inc.
3.14%76.8418.8%$224.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.83%119.261.6%$202.56m
TSROTESARO, Inc.
4.15%160.0016.1%$189.31m
ESPREsperion Therapeutics, Inc.
-3.61%38.9418.7%$173.60m
ILMNIllumina, Inc.
1.72%170.583.7%$172.89m
AUPHAurinia Pharmaceuticals Inc.
-4.41%8.026.3%$150.20m
CLVSClovis Oncology, Inc.
2.61%70.3217.5%$142.57m
VRTXVertex Pharmaceuticals Incorporated
1.04%89.982.2%$135.11m
EXELExelixis, Inc.
2.95%20.917.0%$105.88m

Company Profile

Anavex Life Sciences Corp. engages in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. It's lead compound, ANAVEXTM 2-73, is being developed to treat Alzheimer's disease, Parkinson's disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.